Lantern Pharma up on positive pre-clinical data of cancer drug

Lantern Pharma

15/12/2022 15:29

** Shares of drug developer Lantern Pharma Inc  LTRN.O  rise
3% to $5.60 in morning trade
    ** Company announces new positive pre-clinical data for its
drug candidate to treat mantle cell lymphoma (MCL)
    ** MCL is a type of cancer that affects the lymphatic
system, a part of the body's immune system
    ** Treatment reduces tumor growth significantly vs
standard-of-care agents in pre-clinical study involving mice
implanted with MCL cell - Lantern
    ** Company sees to seek trial permission in early 2023 and
start human trials by mid-2023
    ** Stock down 31% YTD
 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com))